Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avidity Biosciences Inc RNA

Healthcare Biotechnology
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA... see more

Recent & Breaking News (NDAQ:RNA)

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire 3 days ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire January 8, 2025

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025

PR Newswire January 8, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire December 20, 2024

Avidity Biosciences to Participate in Upcoming Investor Conference

PR Newswire November 26, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire November 21, 2024

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations

PR Newswire November 12, 2024

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights

PR Newswire November 7, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

PR Newswire October 31, 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE(TM) Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy

PR Newswire October 30, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire October 21, 2024

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)

PR Newswire October 3, 2024

Avidity Biosciences to Participate in Upcoming Investor Conference

PR Newswire September 25, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire September 23, 2024

Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month

PR Newswire September 5, 2024

Avidity Biosciences to Participate in Upcoming Investor Conferences

PR Newswire August 28, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire August 21, 2024

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire August 19, 2024

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

PR Newswire August 14, 2024

Avidity Biosciences Announces Proposed Public Offering of Common Stock

PR Newswire August 13, 2024